NPS Pharmaceuticals (NPSP) Phase 3 GATTEX Met Primary Efficacy Endpoint
Tweet Send to a Friend
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
